EUVIMEDEUVIMED entdecken
Crossref

L26/P-423 Long term follow-up of the reproductive outcomes of cancer survivors who cryopreserved oocytes before gonadotoxic treatments

N. Serra, F. Filippi, S. Comana, M. Reschini, M. Molgora, S. Edgardo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Serra und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What are the reproductive outcomes of young female cancer survivors and what is the contribution of cryopreserved oocytes to the reproductive life of these patients? Summary answer Among women seeking pregnancy after cancer, most live births occurred through natural conception. However, cryopreserved oocytes provided a significant additional contribution. What is known already Fertility preservation by oocyte cryopreservation is widely recommended for young women undergoing gonadotoxic cancer treatments. Available evidence suggests that many cancer survivors may conceive spontaneously, raising questions about the real-life utilization and added value of cryopreserved oocytes. However, long-term data on actual pregnancy seeking behaviours, use of cryopreserved oocytes and reproductive outcomes remain limited. Study design, size, duration Monocentric retrospective observational follow-up study including all women who underwent oocyte cryopreservation before gonadotoxic cancer treatments between December 2012 and December 2022 at the Infertility Unit of Ospedale Policlinico di Milano. As of October 2025, median follow-up was 6 [5-9] years. Participants/materials, setting, methods Oocytes cryopreservation was initiated by 405 patients, but 23 (6%) died and 27 (7%) were lost at follow-up. Finally, 355 women were included in our analysis. Reproductive history was updated through structured medical records and standardized phone questionnaires. Outcomes were analysed among women who actively sought pregnancy after cancer treatment, distinguishing spontaneous conceptions from pregnancies achieved using cryopreserved oocytes. Main results and the role of chance At follow-up, 140 (39.4%) cancer survivors had tried to conceive. Median age at cancer diagnosis was 32 [28–36] years, 54% of the cohort being diagnosed with breast cancer while 31% had an onco-haematological diagnosis. The vast majority (94%) had a recovery of menstrual cycles after treatments. Ninety-six women (68.6%) achieved at least one pregnancy and 84 (60%) had at least one live birth, for a total of 108 live-born children. Spontaneous conception accounted for most of the reproductive success with 64 women (45.7%) achieving at least one live birth. Overall, 55 women returned to use their cryopreserved oocytes, representing a return rate of 13.5% of the full cohort. Median time interval from cryopreservation to oocytes thawing was 4 [3–6] years. Median age at cryopresevation and at thawing was 35 [31–37] and 38 [35–41] years, respectively. Twenty-one patients had a live-born child with cryopreserved oocytes. The live birth rate per woman using cryopreserved oocytes was 38.2%. The cumulative live birth rate with and without the use of cryopreserved oocytes showed a progressive increase. By the end of follow-up, live-birth probability was about 20% greater in the group that incorporates fertility preservation techniques. Limitations, reasons for caution The retrospective design and single-centre setting may limit generalizability. Selection bias cannot be excluded. The impact of oocytes freezing is maybe underestimated because most women did not yet consider additional sibling (women may need frozen oocytes to conceive a second child after spontaneous conception). Wider implications of the findings Most young cancer survivors who seek pregnancy can achieve spontaneous conception. However, oocyte cryopreservation provides a meaningful complementary reproductive option. Our findings support the role of fertility preservation techniques as an additional safeguard rather than a guaranteed pathway to parenthood Trial registration number No

Zitieren

APA

Serra, N., Filippi, F., Comana, S., Reschini, M., Molgora, M., & Edgardo, S. (2026). L26/P-423 Long term follow-up of the reproductive outcomes of cancer survivors who cryopreserved oocytes before gonadotoxic treatments. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.757

Vancouver

Serra N, Filippi F, Comana S, Reschini M, Molgora M, Edgardo S. L26/P-423 Long term follow-up of the reproductive outcomes of cancer survivors who cryopreserved oocytes before gonadotoxic treatments. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.757

BibTeX
@article{Serra2026,
  author = {Serra, N. and Filippi, F. and Comana, S. and Reschini, M. and Molgora, M. and Edgardo, S.},
  title = {L26/P-423 Long term follow-up of the reproductive outcomes of cancer survivors who cryopreserved oocytes before gonadotoxic treatments},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.757}
}
Kostenlos starten →